This virtually live educational activity focuses on leveraging targetable mutations for cancer-directed therapy through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in Non-Hodgkin’s Lymphoma.

RELEASED DATE: July 20, 2023
EXPIRATION DATE: July 20, 2024

This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in multiple myeloma.

RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024

This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about biomarkers that guide treatment selection, novel immunotherapy treatment strategies, and the critical role of multidisciplinary management to individualize care in melanoma.

RELEASED DATE: June 15, 2023
EXPIRATION DATE: June 15, 2024

This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immuno-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in Basal Cell Carcinoma (BCC).

RELEASED DATE: June 22, 2023
EXPIRATION DATE: June 22, 2024

These podcasts are designed to help healthcare professionals assess the relationship between checkpoint inhibition and immunopathology in advanced melanoma, update them on the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma, and provide strategies to optimize the safety of combination immunotherapy approaches in advanced melanoma. Additionally, healthcare professionals will be able to understand the importance of patient advocacy as we converse with a patient about their cancer diagnosis and treatment.

RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024

This Immersive Simulation experience focuses on strategies to overcome resistance to endocrine therapy in early HR+/HER2- breast cancer. Through the Simulation Center activity, healthcare practitioners will develop a plan to help patients consistently and tolerably use oral anti-cancer medications for HR+/HER2- breast cancer. The program will analyze clinical trial data on CDK4/6 inhibitors in early HR+/HER2- breast cancer to optimize monitoring and managing treatment-associated adverse events. Additionally, healthcare practitioners will develop strategies to support patients in their adherence and persistence with agreed-upon treatment plan for HR+/HER2- early breast cancer.

RELEASED DATE: January 30, 2024
EXPIRATION DATE: January 30, 2025

In this brief 30-minute program, noted global expert in lung cancer, Dr. David Planchard, MD, PhD, head of the thoracic cancer group at Gustave Roussy in Villejuif, France, will describe current data informing the management of advanced NSCLC. Based on current clinical evidence, updated guidelines inform the selection of checkpoint inhibition and combinations of checkpoint inhibitors with chemotherapy in the frontline setting. Through appropriate selection of patients for single-agent versus combination regimens in the frontline setting of advanced NSCLC lacking targetable mutations, and awareness of potential adverse events associated with therapy, clinicians will be better equipped to improve therapeutic outcomes for patients.

RELEASED DATE: November 17, 2023
EXPIRATION DATE: November 17, 2024

Aimed toward U.S. community-based oncology care providers who serve patients with melanoma, this educational program will inform on the emerging role of adjuvant immunotherapy in patients who have undergone surgical resection for Stage IIB/C melanoma, and help practitioners integrate these treatment options in their patient care plan. This TeleECHO series will also provide guidance on identifying and mitigating immune-related adverse events in patients with early-stage melanoma receiving immunotherapy.

RELEASED DATE: April 12, 2024
EXPIRATION DATE: April 12, 2025

This program will inform clinicians of the rationale for use of immunotherapy in cutaneous squamous cell carcinoma (cSCC), including the reasoning behind investigations of its use in the neoadjuvant and adjuvant settings. Through the immersive 3D animations, clinicians will be exposed to current perspectives on the pathophysiology of early cSCC, how immunotherapy before and/or after surgery may improve outcomes, and available data from clinical study of neoadjuvant immunotherapy for cSCC.

RELEASED DATE: December 15, 2023
EXPIRATION DATE: December 15, 2024

This case-based enduring TeleECHO educational series will focus on recognizing and managing adverse events associated with antibody-drug conjugate in HER2-targeted therapy for advanced or metastatic breast cancer. Engage with expert discussion to learn more about the benefits of early detection and intervention, and treatment strategies and ways overcome screening barriers in metastatic breast cancer.

RELEASED DATE: November 17, 2023
EXPIRATION DATE: November 17, 2024